Free Trial
NASDAQ:CERS

Cerus (CERS) Stock Price, News & Analysis

Cerus logo
$1.35 -0.01 (-0.74%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$1.38 +0.03 (+2.59%)
As of 04/25/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cerus Stock (NASDAQ:CERS)

Key Stats

Today's Range
$1.31
$1.37
50-Day Range
$1.22
$1.82
52-Week Range
$1.12
$2.54
Volume
1.30 million shs
Average Volume
1.27 million shs
Market Capitalization
$250.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50
Consensus Rating
Buy

Company Overview

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Cerus Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

CERS MarketRank™: 

Cerus scored higher than 51% of companies evaluated by MarketBeat, and ranked 519th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cerus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cerus has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cerus' stock forecast and price target.
  • Earnings Growth

    Earnings for Cerus are expected to grow in the coming year, from ($0.08) to ($0.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cerus is -12.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cerus is -12.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cerus has a P/B Ratio of 4.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Cerus' valuation and earnings.
  • Percentage of Shares Shorted

    5.51% of the float of Cerus has been sold short.
  • Short Interest Ratio / Days to Cover

    Cerus has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Cerus has recently decreased by 3.42%, indicating that investor sentiment is improving.
  • Dividend Yield

    Cerus does not currently pay a dividend.

  • Dividend Growth

    Cerus does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.51% of the float of Cerus has been sold short.
  • Short Interest Ratio / Days to Cover

    Cerus has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Cerus has recently decreased by 3.42%, indicating that investor sentiment is improving.
  • News Sentiment

    Cerus has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Cerus this week, compared to 2 articles on an average week.
  • Search Interest

    Only 2 people have searched for CERS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cerus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $665,210.00 in company stock.

  • Percentage Held by Insiders

    Only 3.40% of the stock of Cerus is held by insiders.

  • Percentage Held by Institutions

    78.37% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cerus' insider trading history.
Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

CERS Stock News Headlines

2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisis
What's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot-com bust, worse than the COVID crash, and even worse than the Great Depression. What's coming, he says, could soon crash the market by 50% or more – and keep it down for 10, 20, or even 30 years.
BTIG Reaffirms Their Hold Rating on Cerus (CERS)
See More Headlines

CERS Stock Analysis - Frequently Asked Questions

Cerus' stock was trading at $1.54 on January 1st, 2025. Since then, CERS shares have decreased by 12.3% and is now trading at $1.35.
View the best growth stocks for 2025 here
.

Cerus Co. (NASDAQ:CERS) announced its quarterly earnings data on Thursday, February, 20th. The biotechnology company reported ($0.01) EPS for the quarter, hitting analysts' consensus estimates of ($0.01). The biotechnology company earned $50.81 million during the quarter, compared to analyst estimates of $50.81 million. Cerus had a negative net margin of 11.60% and a negative trailing twelve-month return on equity of 40.55%.
Read the conference call transcript
.

Cerus' top institutional investors include Sumitomo Mitsui Trust Group Inc. (3.33%), Assenagon Asset Management S.A. (0.66%), Bouvel Investment Partners LLC (0.27%) and Rhumbline Advisers (0.14%). Insiders that own company stock include William Mariner Greenman, Vivek K Jayaraman, Kevin Dennis Green, Richard J Benjamin, Chrystal Jensen, Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Ann Lucena and Hua Shan.
View institutional ownership trends
.

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cerus investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
2/20/2025
Today
4/25/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:CERS
Employees
290
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$3.50
High Stock Price Target
$4.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+159.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-37,490,000.00
Pretax Margin
-11.13%

Debt

Sales & Book Value

Annual Sales
$180.27 million
Price / Cash Flow
N/A
Book Value
$0.29 per share
Price / Book
4.66

Miscellaneous

Free Float
179,401,000
Market Cap
$250.82 million
Optionable
Optionable
Beta
1.70

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:CERS) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners